GLI1 and medulloblastoma: The group tackle this problem by nanoformulating HPI-1 (NanoHHI) that is a strong antagonist of Gli1 and found that NanoHHI strikingly inhibits the growth of mouse medulloblastoma allografts, which shelter a SmoD477G-binding site mutation, together with substantial downregulation of Gli1 mRNA.